Department of Endocrine, Shenzhen Bao'an Chinese Medicine Hospital, Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China.
Department of Seventh College of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Endokrynol Pol. 2024;75(5):494-500. doi: 10.5603/ep.99456. Epub 2024 Oct 8.
Thyroid cancer is a commonly occurring malignant tumour within the endocrine system, the incidence of which has been increasing steadily in our country. It has been the focus and direction of research in recent decades to continuously explore the diagnostic markers and molecular mechanisms of thyroid cancer and provide new possibilities for the healing of patients. In this study, lncRNA DHRS4-AS1 was identified as the research target, and the regulatory function of abnormal expression of DHRS4-AS1 on thyroid cancer was discussed.
Thyroid cancer (116) and non-cancer normal (82) tissue samples were collected in this paper, and the expression of DHRS4-AS1 and miR-222-3p in tissues and cells were evaluated by RT-qPCR. CCK-8 and flow cytometry were used to detect cell survival status. The mechanism of DHRS4-AS1 sponge miR-222-3p was analysed by dual-luciferase reporter gene detection.
In the present study, DHRS4-AS1 was down-regulated in both thyroid tissue and cell samples, while miR-222-3p expression was elevated. The ROC curve reflected the diagnostic value of DHRS4-AS1 in thyroid cancer [area under the curve (AUC) = 0.887, sensitivity = 76.7%, specificity = 95.1%]. DHRS4-AS1 regulates the development of thyroid cancer by targeting miR-222-3p. In addition, in vitro experiments demonstrated that overexpression of DHRS4-AS1 (pcDNA3.1-DHRS4-AS1) inhibited the proliferation of thyroid cancer cells and promoted cell apoptosis, while down-regulating the level of miR-222-3p.
DHRS4-AS1 acts as a miR-222-3p sponge in thyroid cancer, and overexpression of DHRS4 AS1 down-regulates cell proliferation and promotes cell apoptosis. These findings demonstrate the potential of DHRS4-AS1 as a diagnostic factor for thyroid cancer.
甲状腺癌是内分泌系统中常见的恶性肿瘤，其在我国的发病率一直在稳步上升。近几十年来，不断探索甲状腺癌的诊断标志物和分子机制，为患者的治疗提供新的可能，一直是研究的焦点和方向。本研究鉴定 lncRNA DHRS4-AS1 为研究靶点，探讨 DHRS4-AS1 异常表达对甲状腺癌的调控作用。
本文收集甲状腺癌（116 例）和非癌正常（82 例）组织样本，采用 RT-qPCR 检测组织和细胞中 DHRS4-AS1 和 miR-222-3p 的表达。CCK-8 和流式细胞术检测细胞存活状态。通过双荧光素酶报告基因检测分析 DHRS4-AS1 海绵 miR-222-3p 的机制。
本研究中，DHRS4-AS1 在甲状腺组织和细胞样本中均下调，而 miR-222-3p 表达上调。ROC 曲线反映了 DHRS4-AS1 在甲状腺癌中的诊断价值[曲线下面积（AUC）=0.887，灵敏度=76.7%，特异性=95.1%]。DHRS4-AS1 通过靶向 miR-222-3p 调节甲状腺癌的发生发展。此外，体外实验表明，过表达 DHRS4-AS1（pcDNA3.1-DHRS4-AS1）抑制甲状腺癌细胞增殖并促进细胞凋亡，同时下调 miR-222-3p 水平。
DHRS4-AS1 在甲状腺癌中作为 miR-222-3p 的海绵，DHRS4 AS1 的过表达下调细胞增殖并促进细胞凋亡。这些发现表明 DHRS4-AS1 作为甲状腺癌的诊断因子具有潜在价值。
